Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Agilent Technologies, Inc. delivered a solid result and managed an all-around beat in the quarter.</li><li>Despite a 9.7% decline in revenue to $1.69 billion, the team managed to surpass expectations by maintaining a robust fourth-quarter operating margin of 27.8%.</li><li>Despite an 18% core decline in the Life Science and Applied Markets Group, there is optimism about sustained growth in PFAS solutions and Advanced Materials.</li></ul>

Agilent Technologies, Inc. delivered a solid result and managed an all-around beat in the quarter.Despite a 9.7% decline in revenue to $1.69 billion, the team managed to surpass expectations by maintaining a robust fourth-quarter operating margin of 27.8%.Despite an 18% core decline in the Life Science and Applied Markets Group, there is optimism about sustained growth in PFAS solutions and Advanced Materials.

Agilent Technologies Inc.: Key Strategies Fueling Their Industry Breakthrough! - Major Drivers

<ul><li>Agilent Technologies delivered an all-around beat in the most recent quarterly result, with revenue of $1.67 billion, higher than the team had anticipated.</li><li>The pharma market in China is down 30%, which is the main reason for their overall pharma business decline.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Agilent Technologies delivered an all-around beat in the most recent quarterly result, with revenue of $1.67 billion, higher than the team had anticipated.The pharma market in China is down 30%, which is the main reason for their overall pharma business decline.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Agilent Technologies: Acquisition Of Molecular Imaging Corp & Other Major Drivers

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/takara-bio-inc" target="_blank" data-smartkarma-citation="entities:10766:1" rel="noopener">Takara Bio Inc (4974 JP)</a> is anticipating 32% YoY decline in revenue to ¥53B in FY24. Both operating and net profits are expected to decline more than 60% YoY in FY24.</li>
<li>The company has formulated the medium-term management plan 2026 for the three-year period ending in FY26, with the final-year quantitative targets being operating profit of ¥15 billion and ROE 8%.</li>
<li>Considering Takara Bio’s FY24 operating profit guidance of ¥8B, FY26 target seems to be aggressive and difficult to achieve.</li>
</ul>



Takara Bio Inc (4974 JP) is anticipating 32% YoY decline in revenue to ¥53B in FY24. Both operating and net profits are expected to decline more than 60% YoY in FY24.
The company has formulated the medium-term management plan 2026 for the three-year period ending in FY26, with the final-year quantitative targets being operating profit of ¥15 billion and ROE 8%.
Considering Takara Bio’s FY24 operating profit guidance of ¥8B, FY26 target seems to be aggressive and difficult to achieve.


Takara Bio (4974 JP): Corona Cliff Set to Jeopardize FY24 Financial; Formulated FY26 Management Plan

<ul><li>Agilent Technologies managed to exceed analyst expectations in terms of revenue as well as earnings.</li><li>The company's expectations were exceeded by Q2 revenue of $1.72 billion.</li><li>We give Agilent Technologies Inc. a 'Hold' rating with a revised target price.</li></ul>

Agilent Technologies managed to exceed analyst expectations in terms of revenue as well as earnings.The company's expectations were exceeded by Q2 revenue of $1.72 billion.We give Agilent Technologies Inc. a 'Hold' rating with a revised target price.

Agilent Technologies: Notable Progress In Oncology Research & Other Drivers

Equity Capital Markets

Esco Lifesciences Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/esco-lifesciences-group" target="_blank" data-smartkarma-citation="entities:36570:1" rel="noopener">Esco Lifesciences Group (1891571D SP)</a>, a profitable lifesciences tool provider with a global presence, is looking to raise $300M in its upcoming HK IPO.  </li>
<li>The company clocked revenue of S$117M in 2019, which steadily rose to S$155M in 2020 and S$172M in 2021, representing CAGR of 21%, outpacing lifesciences equipment market growth of 10%.</li>
<li>In May 2021, Esco raised $200M through series-A fund raising with investors holding nearly 24% of the shares. This puts its valuation at around $840M.</li>
</ul>



Esco Lifesciences Group (1891571D SP), a profitable lifesciences tool provider with a global presence, is looking to raise $300M in its upcoming HK IPO.  
The company clocked revenue of S$117M in 2019, which steadily rose to S$155M in 2020 and S$172M in 2021, representing CAGR of 21%, outpacing lifesciences equipment market growth of 10%.
In May 2021, Esco raised $200M through series-A fund raising with investors holding nearly 24% of the shares. This puts its valuation at around $840M.


Esco Lifesciences (1891571D SP) Pre-IPO: A Profitable Revenue Growth Saga

United States

Agilent Technologies, Inc. provides core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences, and chemical analysis industries. The Company offers electronic and bio-analytical measurement, semiconductor, and board testing.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Agilent Technologies (A US)

Agilent Technologies Inc.: Key Strategies Fueling Their Industry Breakthrough! - Major Drivers

Agilent Technologies, Inc. delivered a solid result and managed an all-around beat in the quarter. Despite a 9.7% decline in revenue to $1.69...

Baptista Research

Agilent Technologies: Acquisition Of Molecular Imaging Corp & Other Major Drivers

Agilent Technologies delivered an all-around beat in the most recent quarterly result, with revenue of $1.67 billion, higher than the team had...

Baptista Research

Takara Bio (4974 JP): Corona Cliff Set to Jeopardize FY24 Financial; Formulated FY26 Management Plan

Takara Bio is anticipating 32% decline in revenue in FY24. Both operating and net profits are expected to decline 60%+ in FY24. The company aims to...

Tina Banerjee

Agilent Technologies: Notable Progress In Oncology Research & Other Drivers

Agilent Technologies managed to exceed analyst expectations in terms of revenue as well as earnings. The company's expectations were exceeded by...

Baptista Research

Esco Lifesciences (1891571D SP) Pre-IPO: A Profitable Revenue Growth Saga

Esco Lifesciences is looking to raise $300M through HK IPO. During 2019–2021, by leveraging on demand for its products, the company recorded...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)